ArticleInternational journal of oncology2019

Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status.

Sae Ishihara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.